Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Blood (2025) 146 (Supplement 1): 5514.

https://doi.org/10.1182/blood-2025-5514

Published: 2025

Journal Articles

Patient reported outcome design, conduct and reporting in australasian leukaemia & lymphoma group (ALLG) cooperative group trials

Arina Martynchyk, Jodie Palmer, Martina Chiarezza, Eliza Hawkes, Claudia Routherford, Nicole Wong Doo

Blood (2025) 146 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2025-4631

Published: 2025

Journal Articles

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

Blood (2025) 146 (Supplement 1): 1005.

https://doi.org/10.1182/blood-2025-1005

Published: 2025

Journal Articles

EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort

Blood (2025) 146 (Supplement 1): 52.

https://doi.org/10.1182/blood-2025-52

Published: 2025

Journal Articles

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Blood (2025) 146 (Supplement 1): 3601.

https://doi.org/10.1182/blood-2025-3601

Published: 2025

Journal Articles

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Blood (2025) 146 (Supplement 1): 884.

https://doi.org/10.1182/blood-2025-884

Published: 2025

Journal Articles

Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.0

Blood (2025) 146 (Supplement 1): 3651.

https://doi.org/10.1182/blood-2025-3651

Published: 2025

Journal Articles

PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course

Blood (2025) 146 (Supplement 1): 129.

https://doi.org/10.1182/blood-2025-129

Published: 2025

Journal Articles

Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphoma

Kate Manos, Melinda Burgess, Geoffrey Chong, Sze-Ting Lee, Charmaine Smith, William Renwick, Sarah Kempe, Valentine Murigneux, Rakin Chowdhury, Piers Blombery, Niles Nelson, Tineke Fancourt, Joanne Hawking, Wendi Lin, Allison Barraclough, Joel Wight, Colm Keane, Eliza Hawkes

Blood (2025) 146 (Supplement 1): 3306.

https://doi.org/10.1182/blood-2025-3306

Published: 2025

Journal Articles

Divergent immune programs in EBV⁺ PCNSL: A multiomic study of AR-PCNSL and cns-PTLD

Melinda Burgess, Zachary Hawula, Sarah Kempe, Valentine Murigneux, Fiona Swain, Rakin Chowdhury, Nella Tuczko, Lucy Bradbury, Magdalena Antczak, Ahmed Mehdi, Eliza Hawkes, Joel Wight, Clare Gould, Maher Gandhi, Sizun Jiang, Alanna Maguire, Colm Keane

Blood (2025) 146 (Supplement 1): 457.

https://doi.org/10.1182/blood-2025-457

Published: 2025

Journal Articles

Distinct immune checkpoint landscapes in PCNSL and SCNSL revealed by single-nucleus profiling

Zachary Hawula, Nella Tuczko, Melinda Burgess, Lucy Bradbury, Rakin Chowdhury, Fiona Swain, Eliza Hawkes, Joel Wight, Colm Keane

Blood (2025) 146 (Supplement 1): 149.

https://doi.org/10.1182/blood-2025-149

Published: 2025

Journal Articles

Multiomic dissection of immune-privileged DLBCL reveals divergent immune subtypes in testicular and primary central nervous system lymphoma

Melinda Burgess, Zachary Hawula, Nella Tuczko, Sarah Kempe, Valentine Murigneux, Fiona Swain, Rakin Chowdhury, Lucy Bradbury, Magdalena Antczak, Ahmed Mehdi, Eliza Hawkes, Joel Wight, Andrea Henden, Joshua Sheehy, Maher Gandhi, Sizun Jiang, Colm Keane

Blood (2025) 146 (Supplement 1): 147.

https://doi.org/10.1182/blood-2025-147

Published: 2025

Journal Articles

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy

Eliza Hawkes, Clementine Sarkozy, Yuqin Song, Muhit Ozcan, Franck Morschhauser, Alex Herrera, Alev Akyol, Parth Rao, Antonia Di Micco, Adrien Petel, Serena Perna, Charalambos Andreadis

Blood (2025) 146 (Supplement 1): 3615.

https://doi.org/10.1182/blood-2025-3615

Published: 2025

Journal Articles

An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma

Blood (2025) 146 (Supplement 1): 5338.

https://doi.org/10.1182/blood-2025-5338

Published: 2025

Journal Articles

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Blood (2022) 140 (Supplement 1): 573–576.

https://doi.org/10.1182/blood-2022-163371

Published: 2022

Journal Articles

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

Zhong Goh, Maya Latimer, Katharine L. Lewis, Chan Yoon Cheah, Pietro Di Ciaccio, Tania Cushion, Eliza Hawkes, Sean Harrop, Matthew Ku, Ashlea Campbell, Nada Hamad, Erica M. Wood, Eliza Chung, Pin-Yen Chen, Tara Cochrane

Blood (2022) 140 (Supplement 1): 9413–9415.

https://doi.org/10.1182/blood-2022-156782

Published: 2022

Journal Articles

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 2292–2295.

https://doi.org/10.1182/blood-2022-157194

Published: 2022

Journal Articles

First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

Eliza Hawkes, Katharine L. Lewis, Nicole Wong Doo, Sushrut S. Patil, Hari P. Miskin, Peter Sportelli, Kathryn S. Kolibaba, Emmanuel Normant, Tejasvi Turpuseema, Chan Y. Cheah

Blood (2022) 140 (Supplement 1): 6599–6601.

https://doi.org/10.1182/blood-2022-169171

Published: 2022

Journal Articles

Development and Validation of the a dvanced-Stage H odgkin Lymphoma (HL) I nternational P rognostication I ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

Angie Mae Rodday, Susan K. Parsons, Jonathan W. Friedberg, Andrea Gallamini, Eliza Hawkes, David C. Hodgson, Peter Johnson, Brian K. Link, Eric Mou, Kerry J. Savage, Jenica Upshaw, Pier Luigi Zinzani, Matthew J. Maurer, Andrew M. Evens

Blood (2022) 140 (Supplement 1): 760–762.

https://doi.org/10.1182/blood-2022-164720

Published: 2022

Journal Articles

The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

Julio C. Chavez, Neta Goldschmidt, Felipe Samaniego, Tomasz Wrobel, Federica Cavallo, Gustavo Fonseca, Sung-Soo Yoon, Lubos Drgona, Eliza Hawkes, Itai Levi, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nathan H. Fowler, Pier Luigi Zinzani

Blood (2021) 138 (Supplement 1): 45.

https://doi.org/10.1182/blood-2021-147425

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Surovatamig (AZD0486), a CD19xCD3 T-cell engager (TCE), demonstrates high rate of minimal residual disease (MRD)–Negative complete responses in Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including in patients who previously progressed on CD20 TCE and CD19 CAR T-cell therapies

Patient reported outcome design, conduct and reporting in australasian leukaemia & lymphoma group (ALLG) cooperative group trials

Three-year follow-up of the Phase 1 first-in-human study investigating surovatamig, a novel CD19xCD3 T-cell engager, in patients with Relapsed/Refractory (R/R) follicular lymphoma (FL)

EZH2 and CREBBP mutation status identify a subset of patients who benefit from bendamustine- over CHOP/CVP-based immunochemotherapies in follicular lymphoma: Findings from the GALLIUM trial and validation in a large international cohort

Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation

Acalabrutinib plus venetoclax and rituximab in patients with treatment-naive (TN) mantle cell lymphoma (MCL): Results from the Phase 2 TrAVeRse study

Performance of radiomics features in patients with peripheral T-cell lymphoma: Data from international prospective T-cell project 2.0

PET-adaptive beacopp- versus ABVD-based therapies for advanced-stage (AS) classic Hodgkin lymphoma (cHL): Survival comparisons leveraging a multi-state model and analyzing the impact of a-hipi scores across the disease course

Expression of the cancer testis antigen PRAME is associated with response to immune checkpoint inhibitor and rituximab priming in treatment-naïve diffuse large B-cell lymphoma

Divergent immune programs in EBV⁺ PCNSL: A multiomic study of AR-PCNSL and cns-PTLD

Distinct immune checkpoint landscapes in PCNSL and SCNSL revealed by single-nucleus profiling

Multiomic dissection of immune-privileged DLBCL reveals divergent immune subtypes in testicular and primary central nervous system lymphoma

Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy

An immunometabolic companion biomarker to enhance FDG-PET interpretation and guide frontline therapy in follicular lymphoma

Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study

FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma

First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

Development and Validation of the a dvanced-Stage H odgkin Lymphoma (HL) I nternational P rognostication I ndex (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium

The Combination of Umbralisib Plus Ublituximab Is Active in Patients with Relapsed or Refractory Marginal Zone Lymphoma (MZL): Results from the Phase 2 Global Unity-NHL Trial

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only